Bausch Health director sells 24,456 shares

Bausch Health Companies Inc. director Frank D. Lee reported an open-market sale of common shares.

Rhea-AI Filing Summary

Bausch Health Companies Inc. director Frank D. Lee reported an open-market sale of common shares. On May 19, 2026, he sold 24,456 common shares at an average price of $5.43 per share. Following this transaction, he directly holds 49,339 common shares.

According to the footnote, the shares were sold in the open market under a Rule 10b5-1 trading plan to fund estimated tax obligations from a previously vested equity award granted to the company’s non-employee directors. The filing shows no derivative positions remaining in this report.

Insider Trade Summary 10b5-1

Net Seller: 24,456 shares

Net Sell 1 txn

Insider Lee Frank D.

Role Director

Sold 24,456 shs ($133K)

Type	Security	Shares	Price	Value
Sale	Common Shares, No Par Value	24,456	$5.43	$133K

Holdings After Transaction: Common Shares, No Par Value — 49,339 shares (Direct)

Footnotes (1)

1. F1. Represents shares of the Issuer's common stock, no par value, sold in the open market pursuant to a Rule 10b5-1 trading plan to fund estimated tax obligations arising from a previously vested equity award granted to the Issuer's non-employee directors.

Key Figures

Shares sold: 24,456 shares Sale price per share: $5.43 per share Shares held after transaction: 49,339 shares +1 more

4 metrics

Shares sold 24,456 shares Open-market sale of common shares on May 19, 2026

Sale price per share $5.43 per share Average price for the 24,456 common shares sold

Shares held after transaction 49,339 shares Direct common share holdings following the reported sale

Net shares sold 24,456 shares Net sell direction from transaction summary

Key Terms

Rule 10b5-1 trading plan, previously vested equity award, non-employee directors, Common Shares, No Par Value

4 terms

Rule 10b5-1 trading plan regulatory

"sold in the open market pursuant to a Rule 10b5-1 trading plan to fund estimated tax obligations"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

previously vested equity award financial

"tax obligations arising from a previously vested equity award granted to the Issuer's non-employee directors"

non-employee directors financial

"previously vested equity award granted to the Issuer's non-employee directors"

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

Common Shares, No Par Value financial

"security_title": "Common Shares, No Par Value""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bausch Health (BHC) report for director Frank D. Lee?

Bausch Health reported that director Frank D. Lee sold 24,456 common shares in an open-market transaction at an average price of $5.43 per share. This Form 4 filing reflects a single sale of non-derivative common shares on May 19, 2026.

Why did Bausch Health director Frank D. Lee sell 24,456 BHC shares?

The sale was made to fund estimated tax obligations arising from a previously vested equity award granted to Bausch Health’s non-employee directors. The filing states the transaction occurred under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.

How many Bausch Health shares does Frank D. Lee hold after this Form 4 transaction?

After selling 24,456 common shares, Frank D. Lee directly holds 49,339 Bausch Health common shares. This post-transaction ownership figure is disclosed in the Form 4 and represents his remaining direct stake reported in this filing.

Was the Bausch Health (BHC) insider sale by Frank D. Lee part of a Rule 10b5-1 plan?

Yes. The filing explains that the common shares were sold in the open market pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged trading programs designed to allow insiders to sell shares on a predetermined schedule.

Did the Bausch Health Form 4 involve derivative securities for Frank D. Lee?

No. The disclosed transaction involves non-derivative common shares with no associated options or other derivatives exercised or converted. The derivative summary section in the data is empty, indicating no derivative transactions were reported in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 05:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Frank D.

(Last) (First) (Middle)

400 SOMERSET CORPORATE BLVD.

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bausch Health Companies Inc. [ BHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, No Par Value	05/19/2026		S		24,456(1)	D	$5.43	49,339	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock, no par value, sold in the open market pursuant to a Rule 10b5-1 trading plan to fund estimated tax obligations arising from a previously vested equity award granted to the Issuer's non-employee directors.

	/s/ Brianna M. Dorsi, attorney-in-fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)